Posted by Michael Wonder on 31 Jul 2025
Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma
29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use of glofitamab in combination with gemcitabine hydrochloride and oxaliplatin in the NHS in England.
For the time being, glofitamab, when used in combination with gemcitabine hydrochloride and oxaliplatin, should not be used for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified who are ineligible for autologous stem cell transplantation.
